ProQR Therapeutics N.V. (PRQR) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, targeting Leber Congenital Amaurosis 10 (LCA10).
Analysis Summary
ProQR Therapeutics N.V. reported revenue of $15.3M in the most recent fiscal year, growing at a 5-year CAGR of 71.5%.
Trailing-twelve-month margins: gross margin 92.3%, operating margin -232.7%, net margin -228.3%.
At the current price of $1.86, PRQR has negative trailing earnings (P/E not meaningful) and an ROE of -68.44%. Market capitalisation stands at $196M.
Balance sheet quality for PRQR: current ratio of 3.1, net cash position of $92.1M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $1.86 |
| Market Cap | $196M |
| Exchange | NASDAQ |
| Country | NL |
Valuation Ratios
| Price / Book | 2.09 |
| EV / EBITDA | -2.27 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -68.44% |
| Return on Invested Capital | -41.91% |
| Return on Assets | -31.76% |
| Gross Margin | 92.33% |
| Operating Margin | -232.71% |
| Net Margin | -228.29% |
Financial Health
| Debt / Equity | 0.17 |
| Current Ratio | 3.49 |
| Piotroski F-Score | 0 |
| Altman Z-Score | -4.56 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| PRQR | ProQR Therapeutics N.V. | $196M | 2.09 | -68.4% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price Performance
| 1 month | -13.49% |
| 3 months | -1.59% |
| Year-to-date | -7.92% |
| 1 year | -9.71% |
| 3 years | +20.78% |
| 5 years | -78.04% |
52-Week Range
| 52-week High | $3.10 |
| 52-week Low | $1.33 |
| Avg Volume (90d) | 947K |
Related companies: ACHV · ALLO · ARCT · CAPR · EDIT · IMMP · MREO
Explore sector: Healthcare · Biotechnology
More sections of PRQR: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks